The Silent Threat of Cardiovascular Disease
Cardiovascular disease (CVD) is a global health crisis, silently claiming countless lives. The SARC-CalF score, a crucial indicator of cardiovascular risk, is often overlooked, leading to delayed interventions and devastating consequences.
The Cost of Ignoring SARC-CalF
The implications of missed or delayed CVD diagnosis are far-reaching. Patients face increased risk of heart attacks, strokes, and other life-threatening events. Healthcare systems grapple with higher treatment costs and resource strain.
Kribado: Your Shield Against Cardiovascular Risk
Kribado, the next-generation patient screening device, empowers healthcare providers to proactively address CVD. By instantly calculating the SARC-CalF score, Kribado enables early identification of high-risk patients, facilitating timely interventions and improved patient outcomes.
How Kribado Works
Kribado’s user-friendly interface and advanced algorithms streamline the patient screening process. A brief questionnaire followed by an instant risk score empowers healthcare professionals to make data-driven decisions.
The Kribado Advantage
Indigital Technologies, a leader in pharmaceutical business growth, has developed Kribado to bridge the gap in CVD prevention. Our device is backed by extensive research and is trusted by healthcare providers worldwide.
Empower Your Practice with Kribado
Kribado is more than a device; it’s a strategic asset. By integrating Kribado into your practice, you can enhance patient care, improve operational efficiency, and strengthen your reputation as a proactive healthcare provider.